Cargando…

Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study

Background and aim: Autosomal recessive hypercholesterolemia (ARH) is a rare autosomal recessive disorder of low-density lipoprotein (LDL) metabolism caused by pathogenic variants in the LDLRAP1 gene. Like homozygous familial hypercholesterolemia, ARH is resistant to conventional LDL-lowering medica...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Erasmo, Laura, Giammanco, Antonina, Suppressa, Patrizia, Pavanello, Chiara, Iannuzzo, Gabriella, Di Costanzo, Alessia, Tramontano, Daniele, Minicocci, Ilenia, Bini, Simone, Vogt, Anja, Stewards, Kim, Roeters Van Lennep, Jeanine, Bertolini, Stefano, Arca, Marcello
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442671/ https://www.ncbi.nlm.nih.gov/pubmed/36072671 http://dx.doi.org/10.3389/fgene.2022.937750

Ejemplares similares

Long‐term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia
por: Larrey, Dominique, et al.
Publicado: (2022)

Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey
por: D’Erasmo, Laura, et al.
Publicado: (2021)

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile
por: Lupo, Maria Giovanna, et al.
Publicado: (2021)

Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia
por: Harada-Shiba, Mariko, et al.
Publicado: (2017)

Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia
por: Stefanutti, Claudia
Publicado: (2020)

Gradual dose Titration of Lomitapide may Prevent Therapeutic Delays in Patients with Homozygous Familial Hypercholesterolemia
por: Harada-Shiba, Mariko, et al.
Publicado: (2023)

Lomitapide: a review of its clinical use, efficacy, and tolerability
por: Alonso, Rodrigo, et al.
Publicado: (2019)

Lapatinib, Nilotinib and Lomitapide Inhibit Haemozoin Formation in Malaria Parasites
por: de Sousa, Ana Carolina C., et al.
Publicado: (2020)

Xanthomas Regression in an 8-Year-Old Boy Treated With Lomitapide
por: Kolovou, Genovefa, et al.
Publicado: (2019)

The Beneficial Effect of Lomitapide on the Cardiovascular System in LDLr(−/−) Mice with Obesity
por: Munkhsaikhan, Undral, et al.
Publicado: (2023)

Homozygous Familial Hypercholesterolemia (HoFH) in Saudi Arabia and Two Cases of Lomitapide Use in a Real-World Setting
por: Mahzari, Moeber, et al.
Publicado: (2021)

Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia
por: Blom, Dirk J., et al.
Publicado: (2018)

Dietary Intake during 56 Weeks of a Low-Fat Diet for Lomitapide Treatment in Japanese Patients with Homozygous Familial Hypercholesterolemia
por: Kameyama, Noriko, et al.
Publicado: (2019)

A First-in-Class Drug, Lomitapide, Tailored to Patients with Homozygous Familial Hypercholesterolemia is Just about Meeting with Good News to Them
por: Yoshida, Hiroshi
Publicado: (2017)

Lomitapide treatment in a female with homozygous familial hypercholesterolaemia: a case report
por: Littmann, Karin, et al.
Publicado: (2020)

Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia
por: Ben-Omran, Tawfeg, et al.
Publicado: (2019)

Antibacterial activities and action mode of anti-hyperlipidemic lomitapide against Staphylococcus aureus
por: Zhang, Yufang, et al.
Publicado: (2022)

The Interplay between Angiopoietin-Like Proteins and Adipose Tissue: Another Piece of the Relationship between Adiposopathy and Cardiometabolic Diseases?
por: Bini, Simone, et al.
Publicado: (2021)

Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study
por: Nohara, Atsushi, et al.
Publicado: (2019)

Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)
por: D’Erasmo, Laura, et al.
Publicado: (2021)

Lomitapide, a cholesterol-lowering drug, is an anticancer agent that induces autophagic cell death via inhibiting mTOR
por: Lee, Boah, et al.
Publicado: (2022)

Effectiveness of clinical scores in predicting coronary artery disease in familial hypercholesterolemia: a coronary computed tomography angiography study
por: Catapano, Federica, et al.
Publicado: (2023)

Lomitapide ameliorates middle cerebral artery occlusion‐induced cerebral ischemia/reperfusion injury by promoting neuronal autophagy and inhibiting microglial migration
por: Zheng, Yangmin, et al.
Publicado: (2022)

Repositioning Lomitapide to block ZDHHC5-dependant palmitoylation on SSTR5 leads to anti-proliferation effect in preclinical pancreatic cancer models
por: Wang, Yumeng, et al.
Publicado: (2023)

Sex Differences in Familial Hypercholesterolemia
por: Klevmoen, Marianne, et al.
Publicado: (2023)

The Fibrinogen-like Domain of ANGPTL3 Facilitates Lipolysis in 3T3-L1 Cells by Activating the Intracellular Erk Pathway
por: Bini, Simone, et al.
Publicado: (2022)

Case report: Therapy adherence, MTTP variants, and course of atheroma in two patients with HoFH on low-dose, long-term lomitapide therapy
por: Kayikcioglu, Meral, et al.
Publicado: (2023)

Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long‐Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events
por: D’Erasmo, Laura, et al.
Publicado: (2021)

A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting
por: Blom, Dirk J., et al.
Publicado: (2022)

Is Liver Transplant Curative in Homozygous Familial Hypercholesterolemia? A Review of Nine Global Cases
por: Al Dubayee, Mohammed, et al.
Publicado: (2022)

Integration of sex and gender in cardiovascular medicine: a scientific and clinical imperative
por: Kavousi, Maryam, et al.
Publicado: (2023)

Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia
por: Sharifi, Mahtab, et al.
Publicado: (2017)

Severe Dyslipidemia Mimicking Familial Hypercholesterolemia Induced by High-Fat, Low-Carbohydrate Diets: A Critical Review
por: Houttu, Veera, et al.
Publicado: (2023)

Future risk of cardiovascular disease risk factors and events in women after a hypertensive disorder of pregnancy
por: Benschop, Laura, et al.
Publicado: (2019)

Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study
por: Nam, Chang-Wook, et al.
Publicado: (2019)

Factors Associated with Carotid Atherosclerosis and Achilles Tendon Thickness in Japanese Patients with Familial Hypercholesterolemia: A Subanalysis of the Familial Hypercholesterolemia Expert Forum (FAME) Study
por: Ogura, Masatsune, et al.
Publicado: (2022)

Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia
por: Olmastroni, Elena, et al.
Publicado: (2023)

Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible?
por: Temporelli, Pier Luigi, et al.
Publicado: (2021)

Genetic spectrum of familial hypercholesterolemia and correlations with clinical expression: Implications for diagnosis improvement
por: Di Taranto, Maria Donata, et al.
Publicado: (2021)

Aging, Cardiovascular Risk, and SHBG Levels in Men and Women From the General Population
por: Aribas, Elif, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oc18rkp2n1h96h4s6p3dbqdc95